Abstract
To understand epidermal growth factor receptor (EGFR) and KRAS alterations among tissues of lung cancer patients in Taiwan, and to further understand how they are related, we used tumor tissues from the non-small cell lung cancer patients and performed a complete analysis. In the experimental results, coexisting EGFR and KRAS mutations were found in 1% (2/180) of the samples. This shows that these mutations tend not to coexist. Furthermore, nearly no coexistence was found between KRAS mutations and EGFR overexpression. These outcomes greatly assist the efficacy prediction of current anti-EGFR drugs for cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
